Glaucine

Glaucine

SCHEMBL146441

COc1cc2c(cc1OC)-c1c(OC)c(OC)cc3c1[C@H](C2)N(C)CC3

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2A P28223 14/20 1.00
HTR2B P41595 13/20 1.00
HTR2C P28335 13/20 1.00
HTR7 P34969 12/20 1.00
HTR1A P08908 11/20 1.00
DRD1 P21728 6/20 1.00
DRD2 P14416 5/20 1.00
KDM4E B2RXH2 2/20 1.00
TDP2 O95551 2/20 1.00
ALDH1A1 P00352 2/20 1.00
MAPT P10636 2/20 1.00
CASP3 P42574 2/20 1.00
RAD52 P43351 2/20 1.00
SENP8 Q96LD8 2/20 1.00
SENP7 Q9BQF6 2/20 1.00
SENP6 Q9GZR1 2/20 1.00
HSD17B10 Q99714 1/20 1.00
PTPRCAP Q14761 1/20 1.00
APAF1 O14727 1/20 0.97
HPGD P15428 1/20 0.97

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Glaucine SCHEMBL29735463 1.00 HTR2A (1.00) HTR2AHTR2BHTR2CHTR7HTR1A
Glaucine SCHEMBL30213021 1.00 HTR2A (1.00) HTR2AHTR2BHTR2CHTR7HTR1A
Glaucine SCHEMBL3040938 1.00 HTR2A (1.00) HTR2AHTR2BHTR2CHTR7HTR1A
Glaucine SCHEMBL11158386 0.99 KDM4E (1.00) HTR2AHTR2BHTR2CHTR7HTR1A
Glaucine SCHEMBL11249152 0.99 KDM4E (1.00) HTR2AHTR2BHTR2CHTR7HTR1A
Glaucine SCHEMBL11166124 0.99 HTR2A (0.97) HTR2AHTR2BHTR2CHTR7HTR1A
Glaucine SCHEMBL4312401 0.94 HTR2A (0.88) HTR2AHTR2BHTR2CHTR7HTR1A
Glaucine SCHEMBL7389697 0.93 HTR2B (0.86) HTR2AHTR2BHTR2CHTR7HTR1A
SCHEMBL4854015 0.92 HTR7 (1.00) HTR2AHTR2BHTR2CHTR7HTR1A
SCHEMBL30475142 0.92 HTR7 (1.00) HTR2AHTR2BHTR2CHTR7HTR1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1186 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250255781-A1 PROCESSES FOR PREPARATION OF 3-D PRINTED PHARMACEUTICAL PRODUCTS BRISTOL-MYERS SQUIBB COMPANY (US) 2025-08-14 US claimed
US-12296043-B2 Liquisoft capsules PATHEON SOFTGELS INC. (US) 2025-05-13 US claimed
EP-4510999-A1 PROCESSES FOR PREPARATION OF 3-D PRINTED PHARMACEUTICAL PRODUCTS Bristol-Myers Squibb Company (US) 2025-02-26 EP claimed
US-20250051862-A1 METHODS AND COMPOSITIONS RELATED TO ENGINEERED BIOSENSORS BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2025-02-13 US claimed
CN-119212681-A Method for preparing 3-D printed pharmaceutical products 百时美施贵宝公司 2024-12-27 CN claimed
US-20240316015-A1 COMPOSITION AND METHOD FOR TREATING TUMORS NATURAL MEDICINE INSTITUTE OF ZHEJIANG YANGSHENGTANG CO., LTD. (CN) 2024-09-26 US claimed
US-20240279645-A1 METHODS AND COMPOSITIONS RELATED TO A MODIFIED METHYLTRANSFERASE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2024-08-22 US claimed
US-20240261252-A1 Methods of use and formulations of allosteric modulators of the serotonin, dopamine and other receptor systems for medical, recreational, religious, research and other uses. HELDRETH JR DAVID ALAN (US) 2024-08-08 US claimed
US-20240165020-A1 LIQUISOFT CAPSULES PATHEON SOFTGELS INC (US) 2024-05-23 US claimed
EP-4360653-A2 LIQUISOFT CAPSULES Patheon Softgels Inc. (US) 2024-05-01 EP claimed
EP-0618972-A1 CONSTITUTIVE EXPRESSION OF P450SOY AND FERREDOXIN-SOY IN $i(STREPTOMYCES), AND BIOTRANSFORMATION OF CHEMICALS BY RECOMBINANT ORGANISMS E.I. DU PONT DE NEMOURS AND COMPANY (US) 1994-10-12 EP claimed
US-5256190-A Comprising a plate coating, fountain concentrates, an alcohol replacement, a roller coating, plate wash and compensator solution BARTH THOMAS M (US) 1993-10-26 US claimed
WO-1993012236-A1 CONSTITUTIVE EXPRESSION OF P450SOY AND FERREDOXIN-SOY IN STREPTOMYCES, AND BIOTRANSFORMATION OF CHEMICALS BY RECOMBINANT ORGANISMS E.I. DU PONT DE NEMOURS AND COMPANY (US) 1993-06-24 WO claimed
US-5156847-A Aporphinoid alkaloid in nonaqueous solvent Lewis, Walter H. (US) 1992-10-20 US claimed
US-4370331-A L-Glaucine containing composition for cough relief KARL O. HELM AKTIENGESELLSCHAFT (DE) 1983-01-25 US claimed
US-4315010-A ANTITUSSIVE THE DOW CHEMICAL COMPANY (US) 1982-02-09 US claimed
US-4279914-A 1-GLAUCINE OR TETRAHYDROXYAPORPHINE, ANTICOAGULANTS HERMANN GOTTFRIED SCHNABEL FA. (DE) 1981-07-21 US claimed
US-4265912-A Glaucine lactate salts THE DOW CHEMICAL COMPANY (US) 1981-05-05 US claimed
US-4185119-A Antiallergic methods FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1980-01-22 US claimed
US-4183939-A Glaucine analgesic method THE DOW CHEMICAL COMPANY (US) 1980-01-15 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240316015-A1 COMPOSITION AND METHOD FOR TREATING TUMORS PDE4B, PDE4A, PDE4C HTR2A 4201/4885HTR2B 3431/4885HTR2C 4141/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.